What is it about?
A 2 day outpatient infusion of low-dose anti-thymocyte globulin (ATG) can preserve beta cell function (extend honeymoon) and reduced A1c in new onset type 1 diabetes.
Featured Image
Why is it important?
Given the low cost of ATG and the fact that it is FDA approved with over 30 years of clinical use/experience this is an immediately translatable option for using immunotherapy to delay progression of beta cell loss in either high risk subjects with multiple antibodies and dysglyecmia or in new onset type 1 diabetes
Read the Original
This page is a summary of: Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data, Diabetes, April 2019, American Diabetes Association,
DOI: 10.2337/db19-0057.
You can read the full text:
Contributors
The following have contributed to this page
